COVID-19 mortality may be exacerbated in persons with SUD for several reasons, including downregulation of interferon expression, development of pulmonary edema, increased thrombotic factors, and increased expression of angiotensin-converting enzyme 2 (ACE2) (reviewed in [203], although data to support these potential mechanistic interactions are quite limited currently). This evidence concerns the gene ACE2 and COVID-19.